KRON (Kronos Bio, Inc.) שווי פירמה כולל
Kronos Bio, Inc. (KRON) develops small-molecule therapeutics to combat tumor networks, diversifying risks across various clinical projects. The firm's financial stability depends directly on test results, as it currently lacks a consistent cash flow. The current business valuation stands at . Historical price action complements data regarding the production of pilot batches via external certified contractors.
KRON (Kronos Bio, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
For the cancer therapy scientific leader Kronos Bio, Inc. (KRON), the Enterprise Value metric on the GURU.Markets platform serves as an indicator of the business's real value by combining market capitalization with net debt. This calculation allows an investor to assess the actual cost of acquiring the company, accounting for its cash reserves and liabilities, which is critical for verifying the investment quality of biomedical assets.